Zydus Lifesciences Ltd.
BSE: 532321 | NSE: ZYDUSLIFE
Mid Cap | Pharmaceuticals & Drugs
942.55
3.35 (0.36%) Zydus Lifesciences informs about press release
Date: 19-12-2025Zydus Lifesciences has informed that it enclosed a copy of press release dated December 19, 2025, titled ‘Zydus Lifesciences Limited signs an exclusive agreement with Myriad Genetics of US to launch cancer-risk assessment diagnostic tests in India’.
The above information is a part of company’s filings submitted to BSE.